The role of generic medicines and biosimilars in oncology in low-income countries.
Identifieur interne : 000575 ( PubMed/Corpus ); précédent : 000574; suivant : 000576The role of generic medicines and biosimilars in oncology in low-income countries.
Auteurs : L. Renner ; F A Nkansah ; A N O. DodooSource :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2013.
English descriptors
- KwdEn :
- Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Biosimilar Pharmaceuticals (adverse effects), Biosimilar Pharmaceuticals (economics), Biosimilar Pharmaceuticals (therapeutic use), Cost-Benefit Analysis, Drugs, Generic (economics), Drugs, Generic (therapeutic use), Humans, Neoplasms (drug therapy), Neoplasms (economics), Poverty, World Health Organization.
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Biosimilar Pharmaceuticals.
- chemical , economics : Biosimilar Pharmaceuticals, Drugs, Generic.
- chemical , therapeutic use : Antineoplastic Agents, Biosimilar Pharmaceuticals, Drugs, Generic.
- drug therapy : Neoplasms.
- economics : Neoplasms.
- Cost-Benefit Analysis, Humans, Poverty, World Health Organization.
Abstract
Cancer cases are rising in developing countries which are already grappling with high levels of infectious diseases including human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis (TB) and malaria. The United Nations (UN) including the World Health Organisation (WHO) have called on member states to establish strategies to deal with the increasing burden of non-communicable diseases, including cancer, in developing countries. The complexity of cancer care and management calls for innovative approaches in low resource settings especially since these settings are already grappling with huge challenges in healthcare including lack of funds, weak human resource base and lack of treatment guidelines. Whilst the cost of medications is by no means the only high cost in cancer care, the availability of affordable anti-cancer generic drugs and biologically similar therapeutic agents (biosimilars) will go a long way to reduce overall cost of cancer care. The high cost of anticancer medicines has been cited among the reasons whilst patients default in treatment. Non-proprietary anti-cancer agents--generics and biosimilars--often cost several times lower than their innovator branded counterparts. They can reduce the cost of care significantly and their multi-source origin often provide guarantee in supply. The use of generic and biosimilar products is hinged on the assumption that they are of assured quality and of the same pharmaceutical integrity as their innovator counterparts. The use of these products however is associated with challenges that must be understood and addressed. The quality of all generics and biosimilars should be rigorously controlled and assured. Measures to prevent counterfeit and sub-standard generics and biosimilars should be developed and the cold-chain must be maintained for all biosimilars. In addition to these, the WHO is encouraged to develop a prequalification scheme to assist countries without strong regulatory systems to procure anticancer generics and biosimilars of assured quality.
DOI: 10.1093/annonc/mdt326
PubMed: 23975702
Links to Exploration step
pubmed:23975702Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The role of generic medicines and biosimilars in oncology in low-income countries.</title><author><name sortKey="Renner, L" sort="Renner, L" uniqKey="Renner L" first="L" last="Renner">L. Renner</name><affiliation><nlm:affiliation>Department of Child Health, University of Ghana Medical School, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Nkansah, F A" sort="Nkansah, F A" uniqKey="Nkansah F" first="F A" last="Nkansah">F A Nkansah</name></author><author><name sortKey="Dodoo, A N O" sort="Dodoo, A N O" uniqKey="Dodoo A" first="A N O" last="Dodoo">A N O. Dodoo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23975702</idno><idno type="pmid">23975702</idno><idno type="doi">10.1093/annonc/mdt326</idno><idno type="wicri:Area/PubMed/Corpus">000575</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000575</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The role of generic medicines and biosimilars in oncology in low-income countries.</title><author><name sortKey="Renner, L" sort="Renner, L" uniqKey="Renner L" first="L" last="Renner">L. Renner</name><affiliation><nlm:affiliation>Department of Child Health, University of Ghana Medical School, Accra, Ghana.</nlm:affiliation></affiliation></author><author><name sortKey="Nkansah, F A" sort="Nkansah, F A" uniqKey="Nkansah F" first="F A" last="Nkansah">F A Nkansah</name></author><author><name sortKey="Dodoo, A N O" sort="Dodoo, A N O" uniqKey="Dodoo A" first="A N O" last="Dodoo">A N O. Dodoo</name></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term><term>Antineoplastic Agents (therapeutic use)</term><term>Biosimilar Pharmaceuticals (adverse effects)</term><term>Biosimilar Pharmaceuticals (economics)</term><term>Biosimilar Pharmaceuticals (therapeutic use)</term><term>Cost-Benefit Analysis</term><term>Drugs, Generic (economics)</term><term>Drugs, Generic (therapeutic use)</term><term>Humans</term><term>Neoplasms (drug therapy)</term><term>Neoplasms (economics)</term><term>Poverty</term><term>World Health Organization</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Biosimilar Pharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Biosimilar Pharmaceuticals</term><term>Drugs, Generic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term><term>Biosimilar Pharmaceuticals</term><term>Drugs, Generic</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cost-Benefit Analysis</term><term>Humans</term><term>Poverty</term><term>World Health Organization</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cancer cases are rising in developing countries which are already grappling with high levels of infectious diseases including human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis (TB) and malaria. The United Nations (UN) including the World Health Organisation (WHO) have called on member states to establish strategies to deal with the increasing burden of non-communicable diseases, including cancer, in developing countries. The complexity of cancer care and management calls for innovative approaches in low resource settings especially since these settings are already grappling with huge challenges in healthcare including lack of funds, weak human resource base and lack of treatment guidelines. Whilst the cost of medications is by no means the only high cost in cancer care, the availability of affordable anti-cancer generic drugs and biologically similar therapeutic agents (biosimilars) will go a long way to reduce overall cost of cancer care. The high cost of anticancer medicines has been cited among the reasons whilst patients default in treatment. Non-proprietary anti-cancer agents--generics and biosimilars--often cost several times lower than their innovator branded counterparts. They can reduce the cost of care significantly and their multi-source origin often provide guarantee in supply. The use of generic and biosimilar products is hinged on the assumption that they are of assured quality and of the same pharmaceutical integrity as their innovator counterparts. The use of these products however is associated with challenges that must be understood and addressed. The quality of all generics and biosimilars should be rigorously controlled and assured. Measures to prevent counterfeit and sub-standard generics and biosimilars should be developed and the cold-chain must be maintained for all biosimilars. In addition to these, the WHO is encouraged to develop a prequalification scheme to assist countries without strong regulatory systems to procure anticancer generics and biosimilars of assured quality.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23975702</PMID><DateCreated><Year>2013</Year><Month>08</Month><Day>26</Day></DateCreated><DateCompleted><Year>2014</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>24 Suppl 5</Volume><PubDate><Year>2013</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>The role of generic medicines and biosimilars in oncology in low-income countries.</ArticleTitle><Pagination><MedlinePgn>v29-32</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdt326</ELocationID><Abstract><AbstractText>Cancer cases are rising in developing countries which are already grappling with high levels of infectious diseases including human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS), tuberculosis (TB) and malaria. The United Nations (UN) including the World Health Organisation (WHO) have called on member states to establish strategies to deal with the increasing burden of non-communicable diseases, including cancer, in developing countries. The complexity of cancer care and management calls for innovative approaches in low resource settings especially since these settings are already grappling with huge challenges in healthcare including lack of funds, weak human resource base and lack of treatment guidelines. Whilst the cost of medications is by no means the only high cost in cancer care, the availability of affordable anti-cancer generic drugs and biologically similar therapeutic agents (biosimilars) will go a long way to reduce overall cost of cancer care. The high cost of anticancer medicines has been cited among the reasons whilst patients default in treatment. Non-proprietary anti-cancer agents--generics and biosimilars--often cost several times lower than their innovator branded counterparts. They can reduce the cost of care significantly and their multi-source origin often provide guarantee in supply. The use of generic and biosimilar products is hinged on the assumption that they are of assured quality and of the same pharmaceutical integrity as their innovator counterparts. The use of these products however is associated with challenges that must be understood and addressed. The quality of all generics and biosimilars should be rigorously controlled and assured. Measures to prevent counterfeit and sub-standard generics and biosimilars should be developed and the cold-chain must be maintained for all biosimilars. In addition to these, the WHO is encouraged to develop a prequalification scheme to assist countries without strong regulatory systems to procure anticancer generics and biosimilars of assured quality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Renner</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Child Health, University of Ghana Medical School, Accra, Ghana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nkansah</LastName><ForeName>F A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Dodoo</LastName><ForeName>A N O</ForeName><Initials>AN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059451">Biosimilar Pharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016568">Drugs, Generic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059451" MajorTopicYN="N">Biosimilar Pharmaceuticals</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016568" MajorTopicYN="N">Drugs, Generic</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011203" MajorTopicYN="N">Poverty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23975702</ArticleId><ArticleId IdType="pii">mdt326</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdt326</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000575 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000575 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23975702
|texte= The role of generic medicines and biosimilars in oncology in low-income countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23975702" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |